OptiNose, Inc. has appointed Terry Kohler, a seasoned biotech finance expert with over two decades of experience, as their new Chief Financial Officer. Kohler brings a wealth of knowledge from his previous CFO role at Verrica Pharmaceuticals and various financial positions at Endo International PLC. His appointment is accompanied by a substantial inducement grant of stock options and restricted stock units, intended to incentivize his long-term commitment to the company. Kohler's expertise is expected to be instrumental in driving the company's financial strategy and maximizing the value of their offerings, such as XHANCE, for patients with chronic rhinosinusitis.